Previous Close | 1.5900 |
Open | 1.5300 |
Bid | 1.4000 x 900 |
Ask | 1.4700 x 2900 |
Day's Range | 1.2700 - 1.5750 |
52 Week Range | 0.5570 - 26.4100 |
Volume | |
Avg. Volume | 433,716 |
Market Cap | 77.022M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.7370 |
Earnings Date | Mar 31, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.16 |
Subscribe to Yahoo Finance Plus to view Fair Value for CNTB
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
The Center for Drug Evaluation of the National Medical Products Administration in China has signed off Connect Biopharma Holdings Limited's (NASDAQ: CNTB) primary analysis of its ongoing pivotal trial for its lead product candidate CBP-201 in atopic dermatitis. The company will analyze data from the Stage 1 16-week treatment period based on CBP-201 on 255 patients. As a result, Connect Biopharma plans to report this trial's top-line results by year-end, earlier than initially planned. Also Read:
— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled — — Expected Timing for Potential NDA Approval in China Remains Unchanged and is Targeted for 2025 — SAN DIEGO and TAICANG, SUZHOU, China, July 11, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”) today announced it has been informed by the Center for Drug Evaluation of the National Medical Products Administration (CDE), that it can conduct primary anal